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Abstract
Background: New therapeutic targets for cardiac hypertrophy, an independent risk factor for heart failure and death, are
essential. HNO is a novel redox sibling of NON attracting considerable attention for the treatment of cardiovascular disorders,
eliciting cGMP-dependent vasodilatation yet cGMP-independent positive inotropy. The impact of HNO on cardiac
hypertrophy (which is negatively regulated by cGMP) however has not been investigated.
Methods: Neonatal rat cardiomyocytes were incubated with angiotensin II (Ang II) in the presence and absence of the HNO
donor Angeli’s salt (sodium trioxodinitrate) or B-type natriuretic peptide, BNP (all 1 mmol/L). Hypertrophic responses and its
triggers, as well as cGMP signaling, were determined.
Results: We now demonstrate that Angeli’s salt inhibits Ang II-induced hypertrophic responses in cardiomyocytes, including
increases in cardiomyocyte size, de novo protein synthesis and b-myosin heavy chain expression. Angeli’s salt also
suppresses Ang II induction of key triggers of the cardiomyocyte hypertrophic response, including NADPH oxidase (on both
Nox2 expression and superoxide generation), as well as p38 mitogen-activated protein kinase (p38MAPK). The
antihypertrophic, superoxide-suppressing and cGMP-elevating effects of Angeli’s salt were mimicked by BNP. We also
demonstrate that the effects of Angeli’s salt are specifically mediated by HNO (with no role for NON or nitrite), with
subsequent activation of cardiomyocyte soluble guanylyl cyclase (sGC) and cGMP signaling (on both cGMP-dependent
protein kinase, cGK-I and phosphorylation of vasodilator-stimulated phosphoprotein, VASP).
Conclusions: Our results demonstrate that HNO prevents cardiomyocyte hypertrophy, and that cGMP-dependent NADPH
oxidase suppression contributes to these antihypertrophic actions. HNO donors may thus represent innovative
pharmacotherapy for cardiac hypertrophy.
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Introduction
Cardiac hypertrophy is strongly implicated in the development
of heart failure of almost all etiologies. In addition to heart failure,
it remains an independent risk factor for myocardial infarction and
sudden death [1–3]. Cardiac hypertrophy initially develops in vivo
as an adaptive response to maintain myocardial function, for
example in hypertension when cardiac workload is chronically
elevated [4]. Individual cardiomyocytes hypertrophy, accompa-
nied by re-expression of embryonic genes, a switch in prevalence
of contractile protein expression from a-t ob-myosin heavy chain
and sarcomeric organization [2,3]. Ultimately, hypertrophy may
progress to a maladaptive state, with progressive decline in
ventricular contractility and diastolic function, with adverse
outcomes [4,5]. Current therapies (e.g. renin-angiotensin system
inhibition) slow progression of cardiac hypertrophy, but patients
still die with enlarged hearts. Identification of new therapeutic
targets to prevent or reverse cardiac hypertrophy is essential [3].
We and other have shown that the nitroxyl anion, NO
2, the
one electron reduction product of NO
N, is a novel regulator of
cardiovascular function [3,6–16]. At physiological pH, nitroxyl
exists predominantly in the protonated form as HNO [12]. Similar
to NO
N, HNO mediates potent vasodilatation, largely via sGC
activation and an elevation in cGMP [6,7]. In direct contrast to
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N however, HNO also elicits a marked inotropic effect
(independent of cGMP), that persists even in failing myocardium
in vivo [3,8,9]. Other distinct advantages offered by HNO include
its lack of reactivity with reactive oxygen species (ROS) [14,17–
19], an absence of tolerance development [15,20] and a direct
interaction with thiols [10–12]. Much of this evidence has been
obtained using the HNO donor, Angeli’s salt (sodium trioxodini-
trate, Na2N2O3), which releases both HNO and nitrite [3,12].
Cardiac HNO actions (in contrast to those of NO
N) may thus well
be preserved under conditions of oxidative stress (e.g. cardiac
hypertrophy and heart failure) [3,13]. With these therapeutic
advantages, HNO donors are now in development for clinical
management of acute heart failure events.
cGMP-dependent signaling is a powerful antihypertrophic and
ROS-suppressing mechanism in the heart; much of this work has
emanated from our own studies [3,21–28]. Exploiting cGMP for
the treatment of hypertrophy and heart failure via conventional
NO
N donors is limited however by the rapid reaction of ROS with
NO
N to form peroxynitrite and impairing NO
N bioavailability [3].
Given the ability of HNO to stimulate sGC even in settings of
elevated ROS, we now test the hypothesis that HNO elicits
cGMP-dependent antihypertrophic effects in neonatal rat cardio-
myocytes. Further, given that HNO elicits antioxidant actions in
yeast, cell-free systems and in vascular tissues [13,29], the impact
on cardiomyocyte NADPH oxidase was also determined. BNP, a
cGMP-elevating agent with known antihypertrophic efficacy
[21,24,26], was used for comparison. Our results provide the first
evidence that the HNO donor Angeli’s salt prevents cardiomyo-
cyte hypertrophy, and that cGMP-dependent suppression of
cardiomyocyte NADPH oxidase contributes to these antihyper-
trophic actions.
Materials and Methods
This investigationconforms with both the Guide for the Care and Use
of Laboratory Animals published by the US National Institutes of
Health (NIH Publications No. 85-23, revised 1996) and the
National Health and Medical Research Council of Australia
guidelines, and was approved by the Alfred Medical, Research
and Education Precinct (AMREP) Animal Ethics Committee
(approval E/0698/2008/B). All materials were purchased from
Sigma-Aldrich (St. Louis, USA) exceptwhere indicated, andwereof
analytic grade or higher.
Hypertrophic responses in primary neonatal rat
cardiomyocytes
Hearts were collected from 1- to 2-day-old neonatal rat pups,
promptly after euthanasia by decapitation. Cardiomyocytes were
then isolated, and plated at a density of 1610
3 cells/mm
2 for
determination of all measures except two-dimensional (2D)
cardiomyocyte size, in which cells were plated at a density of
2610
2 cells/mm
2 (to permit delineation of defined single cells, as
previously described) [21]. All materials used for cardiomyocyte
isolation were of tissue culture grade. Following 48 h incubation
under serum-free conditions, cardiomyocytes were incubated for
48 h in the presence and absence of the hypertrophic stimuli
angiotensin II (Ang II, 1 mmol/L, Auspep, Parkville, Australia) or
endothelin-1 (ET1, 60 nmol/L) [21,26,30], and/or the HNO
donor Angeli’s salt (sodium trioxodinitrate, 1 mmol/L unless
otherwise stated [6], added 46/day to compensate for its shorter
half-life, Cayman chemicals, Michigan, USA). BNP (1 mmol/L,
Auspep) and the stable cGMP analog 8-bromo-cGMP (8BrcGMP,
1 mmol/L) were used for comparison [21,26]. Concentrations of
all drugs studied were based on those previously reported, as
indicated. The vehicle control for Angeli’s salt, 0.01 mol/L NaOH
[15], was incorporated into the study design, and was also added
46/day. Markers of cardiomyocyte hypertrophy included 2D area
(mm
2) of live cells (30 individual myocytes measured per
treatment), de novo protein synthesis (determined via incorporation
of [
3H]phenylalanine, Amersham Biosciences, Castle Hill, Aus-
tralia), 4 replicates per treatment), and expression of the pro-
hypertrophic gene, b-myosin heavy chain, as previously described
[21,22,26,30]. Real time PCR reagents were all of molecular
biology grade, and included TaqmanH reverse transcription
reagents, TaqmanH Universal PCR master mix, DNase treatment
kits, fluorogenic probes (Applied Biosystems, Scoresby, Australia),
as well as forward and reverse primers for real-time PCR
(Geneworks, Thebarton, Australia).
Triggers of cardiomyocyte hypertrophy
The impact of Angeli’s salt on key triggers of pathological
hypertrophy included cardiomyocyte expression of the Nox2
Figure 1. Antihypertrophic actions of Angeli’s salt. Ang II (1 mmol/L, 48 h)-stimulated cardiomyocyte hypertrophy is abolished by Angeli’s salt
(AS, 1 mmol/L, added 46/day over 48 h). This is evident on A cardiomyocyte area (n=10 myocyte preparations); B de novo protein synthesis (on
[
3H]phenylalanine incorporation, n=9 myocyte preparations); and C hypertrophic gene expression (using the fetal isoform of the contractile protein,
b-myosin heavy chain, n=6 myocyte preparations). *P,0.05 and ***P,0.001 vs control;
#P,0.05 and
###P,0.001 vs Ang II alone.
doi:10.1371/journal.pone.0034892.g001
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phorylation of p38MAPK, as previously described [21,31]. In
addition, phosphorylation of the cell survival kinase Akt and its
downstream target glycogen synthase kinase-3b (GSK-3b, as well
as of the mitogen-activated protein kinase ERK1/2, were also
determined [30]. For determination of Nox2 expression, cells were
incubated for 48 h in the presence and absence of Ang II or ET1,
and/or Angeli’s salt (replenished 46/day). Relative quantification
of changes in cardiomyocyte expression of the Nox2 subunit of
NADPH oxidase (a major source of ROS), was determined using
real time PCR analysis, with 18S as the endogenous control, as
previously described [21,31]. Cardiomyocyte superoxide genera-
tion was determined using NADPH-driven lucigenin-enhanced
chemiluminescence, an estimate of NADPH oxidase activity,
as previously described [21,31,32]. Cells were incubated for
48 h in the presence or absence of Angeli’s salt, BNP, 8BrcGMP,
with Ang II or ET1, added for the final 24 h. Each measurement
was expressed as relative light units per second (RLU/sec).
Background luminescence (in the absence of cells) was sub-
tracted from the average of 8 readings. Each experiment was
studied with at least 4 replicates, and the average result was taken.
In a separate series of experiments, cardiomyocyte activation
of the mitogen-activated protein kinases ERK1/2 and p38MAPK,
as well as phosphorylation of Akt and glycogen synthase
kinase-3b (GSK-3b, were determined in the presence or absence
of Angeli’s salt for 48 h; Ang II was added only for the final
10 min. Western analyses used phospho-specific antibodies (Cell
Signaling Technology, Danvers, MA), as previously described
[30,32].
HNO/sGC/cGMP signaling
The role of sGC and cGK-I in mediating the actions of Angeli’s
salt in cardiomyocytes was determined using the selective
inhibitors, ODQ (1 mmol/L) [15] and KT5823 (250 nmol/L,
Calbiochem-Novabiochem, La Jolla, CA) [21,26], respectively.
The vehicle control for KT5823 and ODQ (0.01% DMSO) was
also incorporated into study design. The impact of Angeli’s salt on
cardiomyocyte protein levels of cGK-I and sGC (48 h incubation),
and phosphorylation of VASP (10 min incubation, a biomarker of
cGK-I signaling) were determined, via Western analysis, using
primary antibodies from Cell Signaling Technology. Cell-free
purified sGC activity was determined by conversion of GTP
(40 mmol/L, Sigma) to cGMP by sGC (34 ng, Alexis Biochemi-
cals, San Diego, CA) over 10 min, in the presence and absence of
Angeli’s salt [33]. Cardiomyocyte cGMP generation was also,
determined via enzyme immunoassay (Cayman Chemical) follow-
ing 5 and 15 min incubation with either Angeli’s salt or BNP, as
previously described [21].
The relative roles of HNO and NO
N in the actions of Angeli’s salt
were determined firstly on generation of NO
N using an NO
N-sensing
electrode (World Precision Instruments, Sarasota, FL) in the presence
and absence of Angeli’s salt, and results compared to the pure NO
N
donor, DEA/NO (both 0.1–30 mmol/L, Cayman Chemical) [15].
Subsequent studies used the selective scavengers, L-cysteine
(3 mmol/L, for HNO) and 2-(4-carboxyphenyl)-4,4,5,5-tetramethy-
limidazoline-1-oxyl-3-oxide(carboxy-PTIO, 200 mmol/L, for NO
N)
[15].In addition, the potential cGMP-elevating and antihypertrophic
effects of both sodium nitrite (1 mmol/L) and degraded Angeli’s salt
(1 mmol/L, replenished 46/day, obtained by storing Angeli’s salt
solution at room temperaturefor48 h,followed by2 h at37uC,prior
to use), was determined.
Table 1. NaOH (0.01 mol/L), the vehicle used for Angeli’s salt,
does not affect neonatal rat cardiomyocyte responses, alone
or in the presence of Ang II (1 mmol/L).
Control NaOH Ang II
Ang
II+NaOH n
Cell size 10060% 10967% 13169%
** 12562%
* 7
Protein synthesis 10060% 107610% 14269%
* 14367%
* 3
Superoxide 10060% 159622% 233643%
* 212633%
* 4
*P,0.05 and
**P,0.01 vs control.
doi:10.1371/journal.pone.0034892.t001
Figure 2. ROS-suppressing actions of Angeli’s salt. AS (1 mmol/L, added 46/day over 48 h) blocks cardiomyocyte NADPH oxidase activity and
expression. A Ang II (1 mmol/L, final 24 h)-induced superoxide generation (lucigenin chemiluminescence, n=11 myocyte preparations); B Ang II
(1 mmol/L, 48 h)-induced cardiomyocyte Nox2 gene expression (n=8 myocyte preparations). *P,0.05 and ***P,0.001 vs control;
#P,0.05 and
###P,0.001 vs Ang II alone.
doi:10.1371/journal.pone.0034892.g002
Nitroxyl Prevents Cardiomyocyte Hypertrophy
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All results were expressed as mean 6 standard error for each
treatment group, with the number of myocyte preparations
studied denoted by ‘‘n’’. Changes in [
3H]phenylalanine incorpo-
ration, 2D cardiomyocyte size, superoxide generation and cGMP
content were expressed as a percentage of paired control
cardiomyocytes from the same preparation. For changes in both
gene expression (b-myosin heavy chain, Nox2) and protein
(ERK1/2, p38MAPK, Akt, GSK-3b, sGC, cGK-I, P-VASP),
results were expressed as a fold of paired control. Statistical
comparison of $3 different experimental groups was performed
using one way repeated measures analysis of variance to compare
the effect of Ang II with paired control, or of antihypertrophic
interventions (e.g. Angeli’s salt in the presence of Ang II) with
Ang II alone, where n$4. The Student-Newman-Keuls correc-
tion for pairwise multiple comparisons was applied where
required. Where the experiment only used 2 groups, the effect
of Angeli’s salt alone versus control was compared using paired t-
tests. Results with P values,0.05 were considered statistically
significant.
Results
Antihypertrophic actions of Angeli’s salt in neonatal
cardiomyocytes
The hypertrophic stimulus, Ang II (1 mmol/L), induces
hypertrophic responses in neonatal rat cardiomyocytes, increasing
2D area to 184612% of control (Figure 1A, P,0.001), de novo
protein synthesis ([
3H]phenylalanine incorporation) to 14669%
(Figure 1B, P,0.001), and b-myosin heavy chain expression to
2.360.4-fold of paired control myocytes (Figure 1C, P,0.05). The
HNO donor Angeli’s salt (1 mmol/L, added 46/day over 48 h)
exerts marked anti-hypertrophic actions, virtually abolishing the
Ang II-induced increases in 2D area (Figure 1A, P,0.001 vs Ang
II alone), protein synthesis (Figure 1B, P,0.001 vs Ang II alone)
and hypertrophic gene expression (Figure 1C, P,0.05 vs Ang II
alone). Angeli’s salt alone does not significantly affect 2D area,
protein synthesis or b-myosin heavy chain in neonatal cardiomy-
ocytes. Further, as shown in Table 1, the NaOH vehicle used for
Angeli’s salt does not significantly affect cardiomyocyte responses,
either alone or in the presence of Ang II (Table 1).
Figure 3. Impact of Angeli’s salt on cardiomyocyte pro-hypertrophic signaling. AS (1 mmol/L, added 46/day over 48 h) selectively inhibits
Ang II (1 mmol/L, final 10 min)-stimulated p38MAPK phosphorylation of pro-hypertrophic signaling. Ang II-stimulated phosphorylation of ERK1/2 and
Akt (and its downstream target GSK-3b) are preserved. Phosphorylation of A ERK1/2 (n=8 myocyte preparations); B p38MAPK (n=7 myocyte
preparations); C Akt (n=5 myocyte preparations, P,0.05); and D GSK-3b (n=9 myocyte preparations, P,0.01), all as a ratio of total kinase.
Representative images for phospho- and total kinases (from the same blot) are shown in the inset of each panel. *P,0.05 and ***P,0.001 vs control;
#P,0.05 and
###P,0.001 vs Ang II alone.
doi:10.1371/journal.pone.0034892.g003
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cardiomyocytes
Ang II significantly increases NADPH-driven cardiomyocyte
superoxide generation 2.560.4 fold paired control (Figure 2A,
P,0.05). Angeli’s salt completely prevents Ang II induction of
cardiomyocyte superoxide (Figure 2A, P,0.05 vs Ang II alone).
Ang II-induced increases in Nox2 expression (to 3.860.5-fold of
control) are also completely abolished by Angeli’s salt (Figure 2B,
P,0.001 vs Ang II alone). Angeli’s salt alone does not significantly
affect either parameter.
Impact of Angeli’s salt on cardiomyocyte pro-growth
signaling
Ang II (1 mmol/L) activates several pro-hypertrophic signals in
cardiomyocytes, including ERK1/2 (by 1.660.1-fold, Figure 3A,
P,0.001), p38MAPK (2.160.6-fold, Figure 3B, P,0.05), Akt
(3.460.4-fold, Figure 3C, P,0.05), and p70S6-kinase (by 2.060.2-
fold, n=4 cardiomyocyte preparations, P,0.05). Ang II also
decreases activity of GSK-3b (an Akt-sensitive negative regulator of
hypertrophy), as indicated by increased GSK-3b phosphorylation
(by 2.360.4-fold, Figure 3D, P,0.05). Pretreatment with Angeli’s
Figure 4. The antihypertrophic actions of Angeli’s salt utilize sGC/cGMP signaling. A The antihypertrophic action of AS (1 mmol/L, added
46/day over 48 h) on cell size is attenuated by the cGK-I inhibitor KT5823 (KT, 250 nmol/L) and by the sGC inhibitor ODQ (1 mmol/L, n=5 myocyte
preparations); and B the superoxide-suppressing actions of Angeli’s salt are abolished by KT5823 and ODQ (n=8 myocyte preparations).
Furthermore, AS C does not affect cardiomyocyte sGC-b1 protein content (normalized to b-tubulin, n=9 myocyte preparations), but acutely
stimulates each of D purified sGC activity (over 10 min, n=5), E cardiomyocyte cGMP accumulation (over 5 and 15 min, n=3 and n=11 myocyte
preparations, respectively) and F the cGK-I biomarker, VASP phosphorylation (over 10 min, normalized to total VASP, n=7 myocyte preparations).
*P,0.05 and **P,0.005 vs control;
#P,0.05 vs Ang II alone;
{P,0.05 vs Ang II+AS.
doi:10.1371/journal.pone.0034892.g004
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p38MAPK activation (P,0.05 versus Ang II alone), without
significant impact on Ang II-mediated ERK1/2 or Akt activation,
or GSK-3b phosphorylation (Figure 3).
The antihypertrophic actions of Angeli’s salt utilize sGC/
cGMP signaling
Angeli’s salt stimulates sGC to mediate its antihypertrophic and
superoxide-suppressing actions in cardiomyocytes, as shown in
Figure 4. The antihypertrophic effect of Angeli’s salt is significantly
attenuated by co-incubation with either the cGK-I inhibitor
KT5823 (250 nmol/L) or the sGC inhibitor ODQ (1 mmol/L,
Figure 4A, P,0.005 versus Ang II+Angeli’s salt). Neither KT5823
nor ODQ significantly affect neonatal cardiomyocyte size, which
was 104612% and 101614%, respectively (both n=5, relative to
paired controls). Similarly, co-incubation with either KT5823 or
ODQ significantly attenuates the suppression of cardiomyocyte
superoxide generation seen in the presence of Angeli’s salt
(Figure 4B, both P,0.05 versus Ang II+Angeli’s salt). Neither
KT5823, ODQ nor their vehicle alone affects this superoxide
signal (results not shown). Further evidence of Angeli’s salt sGC
stimulation includes direct activation of purified sGC activity,
2.260.4-fold (10 min, n=5); cardiomyocyte sGC protein content
is however unchanged (b1-isoform, Figures 4C and 4D). As shown
in Figure 4E, Angeli’s salt also increases cardiomyocyte cGMP
generation to 186622% after 5 min (n=3) and 201627% after
15 min (n=11). Cardiomyocyte content of both the cGK-I
biomarker, phosphorylated VASP (3.160.8-fold at 10 min,
Figure 4F, P,0.05), and cGK-I protein (2.260.7-fold at 48 h,
n=5 P=0.1 vs control) also tend to increase with Angeli’s
salt.
Angeli’s salt inhibits endothelin-1-stimulated actions in
neonatal cardiomyocytes
Angeli’s salt also attenuates responses to a second hypertrophic
stimulus, endothelin-1 (ET1, 60 nmol/L). ET1 increases cardio-
myocyte 2D area to 13169% of control (Figure 5A, P,0.05),
which is reduced to baseline levels Angeli’s salt (Figure 5A). In
addition, the ability of ET1 to increase NADPH-driven cardio-
myocyte superoxide generation to 7.262.5 fold control (Figure 5B,
P,0.05) and Nox2 expression (to 3.061.1-fold control, Figure 5C,
P,0.05) is significantly attenuated by Angeli’s salt (Figures 5B and
5C, both P,0.05 vs ET1 alone).
BNP mimics the cGMP-dependent cardiomyocyte effects
of Angeli’s salt
Similar to Angeli’s salt, the hypertrophic response to Ang II in
neonatal rat cardiomyocytes is also prevented by the natriuretic
peptide and particulate guanylyl cyclase (pGC) ligand, BNP
(1 mmol/L). BNP reduces the Ang II- induced increase in 2D area
from 19069% to 10863% of control (Figure 6A, P,0.05).
Similarly, Ang II-induced [
3H]phenylalanine incorporation was
reduced from 14968% to 11367% by co-incubation with BNP
(Figure 6B, P,0.001). The Ang II-induced increase in NADPH-
driven cardiomyocyte superoxide generation was also blunted by
BNP, from 2.560.4-fold to 1.160.2-fold control (Figure 6C,
P,0.05); BNP alone did not significantly affect cardiomyocyte
superoxide generation. Co-incubation with the cGK-I inhibitor
KT5823 (250 nmol/L) significantly attenuates the antihyper-
trophic effect of BNP on cell size (Figure 6D, P,0.05 Ang
II+BNP+KT5823 vs Ang II+BNP). Furthermore, BNP increases
cardiomyocyte cGMP to 3.060.3-fold (P,0.01) and 3.260.2-fold
paired control (P,0.001) after 5 and 15 min, respectively
(Figure 6E). Lastly, 8BrcGMP (1 mmol/L) also mimics the
ROS-suppressing actions of both Angeli’s salt and BNP, as shown
in Figure 6F.
The actions of Angeli’s salt are mediated via HNO
To confirm that the actions of Angeli’s salt are mediated via
HNO rather than nitrite (the other metabolite of Angeli’s salt) or
extracellular oxidation of HNO to NO
N, we demonstrate that
neither sodium nitrite nor degraded Angeli’s salt (both 1 mmol/L)
elicit significant inhibition of Ang II-stimulated cardiomyocyte
hypertrophy (Figure 7A). The cardiomyocyte actions of intact
Angeli’s salt are completely prevented by the HNO-selective
scavenger, L-cysteine (3 mmol/L, Figure 7B, P,0.05) but are
unaffected by the NO
N-selective scavenger, carboxy-PTIO
(200 mmol/L). Furthermore, neither sodium nitrite nor degraded
Angeli’s salt (both 1 mmol/L) elicit significant impact on
cardiomyocyte cGMP levels after 15 min, in direct contrast to
paired cardiomyocytes treated with Angeli’s salt (Figure 7C, both
n=5 cardiomyocyte preparations and P=NS vs control). Lastly,
under our cell culture conditions, Angeli’s salt fails to generate
NO
N, even at concentrations 30-fold higher than that used in the
present study (Figure 7D). By contrast, DEA/NO (0.1–30 mmol/
L) releases significant amounts of NO
N in a concentration-
dependent manner (Figure 7D). Together these data indicate that
Figure 5. Angeli’s salt also blunts endothelin-1 (ET1)-induced cardiomyocyte responses. AS (1 mmol/L, added 46/day over 48 h) inhibits
ET1 (60 nmol/L)-stimulated actions in neonatal cardiomyocytes. This is evident on A cardiomyocyte area (n=3 myocyte preparations); B
cardiomyocyte NADPH oxidase activity, on ET1-induced superoxide generation (lucigenin chemiluminescence, n=7 myocyte preparations); and C
cardiomyocyte Nox2 NADPH oxidase gene expression, induced by ET1 (n=4 myocyte preparations). *P,0.05 vs control;
#P,0.05 vs ET1 alone.
doi:10.1371/journal.pone.0034892.g005
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apparent contribution from either NO
N or nitrite.
Discussion
The major finding to emerge from this study is the first evidence
that an HNO donor potently blunts cardiomyocyte hypertrophy.
Angeli’s salt prevents all of the hypertrophic actions of Ang II
in neonatal cardiomyocytes in vitro, including Ang II-induced
increasesincellarea, denovoprotein synthesisandhypertrophicgene
expression on b-myosin heavy chain analysis. Ang II-induced
increases in cardiomyocyte NADPH oxidase expression (of the
sarcolemmal Nox2 subunit) and activity (superoxide generation), as
well as activation of p38MAPK, both implicated as triggers of the
cardiomyocytehypertrophicresponsein vitro,arealso blunted bythe
HNO donor. The HNO donor is equally effective at blunting pro-
hypertrophic and pro-oxidant responses, regardless of the hyper-
trophic stimulus (Ang II vs ET1). Further, no role for extracellular
Figure 6. BNP mimics the antihypertrophic and cGMP-dependent cardiomyocyte effects of Angeli’s salt. BNP (1 mmol/L, over 48 h)
prevents Ang II (1 mmol/L)-stimulated cardiomyocyte hypertrophy. This is evident on both A cell size (n=11 myocyte preparations); and B de novo
protein synthesis (n=9 myocyte preparations, P,0.001); in addition to C cardiomyocyte superoxide generation (n=11 myocyte preparations). D
These antihypertrophic actions of BNP are blocked by the cGK-I inhibitor KT5823 (KT, 250 nmol/L, n=6 myocyte preparations). E BNP acutely
stimulates cardiomyocyte cGMP accumulation, over 5 min and 15 min (both n=5 myocyte preparations). F Furthermore, 8BrcGMP (1 mmol/L, n=4)
also mimics the ROS-suppressing actions of both AS and BNP. *P,0.05, **P,0.01 and ***P,0.001 vs control;
#P,0.05,
##P,0.01 and
###P,0.001
vs Ang II alone,
{P,0.05 vs Ang II+BNP.
doi:10.1371/journal.pone.0034892.g006
Nitroxyl Prevents Cardiomyocyte Hypertrophy
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N ,orofnitrite,intheseactionswasevident.
The cGMP system is a powerful antihypertrophic mechanism in the
heart [3,23–28], and like NO
N, the vascular actions of HNO appear
to be mediated predominantly via the activation of sGC and a
subsequent increase in cGMP [6–8,12]. We now provide evidence
that the HNO donor Angeli’s salt elevates cardiomyocyte cGMP
and directly activates sGC activity. Both the antihypertrophic and
superoxide-suppressing effects of Angeli’s salt are sensitive to both
sGC and cGK-I inhibition. These findings confirm cGMP-
dependence of these cardiac actions of HNO.
Angeli’s salt is considered a classical HNO donor [3,12]. It
dissociates at physiological pH and temperature to yield HNO and
nitrite (NO2
2) [12]. Although nitrite is capable of stimulating
sGC-dependent vasorelaxation [34], it is at least 15,000-fold less
potent a vasodilator as Angeli’s salt [6,16], and only lowers blood
pressure in rats in vivo at high concentrations (0.3–1.0 g/kg body
weight) [34]. Based on our studies with sodium nitrite and
degraded Angeli’s salt; we now report that nitrite has negligible
effects in cardiomyocytes and thus is unlikely to mediate the
antihypertrophic actions of Angeli’s salt. Under certain conditions
(cell-free, in the absence of oxygen), higher concentrations of
Angeli’s salt than utilized in the present study (10 mmol/L) has
been reported to also result in some generation of NO
N [16], likely
via oxidation of HNO to NO
N by Cu
2+ or Cu
2+-containing
enzymes (intracellular or extracellular) [12,34,35]. Whilst we
cannot exclude the possibility of intra-cardiomyocyte oxidation of
HNO to NO
N in our studies, we demonstrate that extracellular
oxidation of HNO does not occur under our experimental
conditions, as even at 30 mmol/L, no detectable NO
N is generated,
in accordance with previous observations in the vasculature [6]. In
addition, we show that cardiomyocyte responses to Angeli’s salt
are significantly attenuated by the selective HNO scavenger L-
cysteine, but are completely unaffected by the NO
N scavenger
carboxy-PTIO, analogous to its vasorelaxation responses [6,7].
The sensitivity of Angeli’s salt to the HNO scavenger lends further
support to HNO (rather than nitrite or NO
N) being the responsible
entity for cardiomyocyte effects. Given that HNO (in contrast to
NO
N) is resistant to scavenging by ROS [12,17–19], Angeli’s salt
retains its advantage over NO
N donors for limiting cardiomyocyte
hypertrophy, particularly in settings of elevated ROS generation.
In the present study, we demonstrate that an HNO donor prevents
cardiomyocyte hypertrophy via cGMP-dependent mechanisms that
Figure 7. The actions of Angeli’s salt are mediated via HNO. A Neither sodium nitrite (1 mmol/L, co-released by AS) nor degraded AS (1 mmol/
L) significantly attenuate Ang II-stimulated cardiomyocyte hypertrophy on 2D area (n=7 myocyte preparations). B The superoxide-suppressing
actions of AS (1 mmol/L, added 46/day over 48 h) are abolished by the HNO-selective scavenger L-cysteine (3 mmol/L) but are preserved in the
presence of the NO
N-selective scavenger carboxy-PTIO (cPTIO, 200 mmol/L, n=6 myocyte preparations, P,0.001). C Neither sodium nitrite (1 mmol/L)
nor degraded AS (1 mmol/L) significantly stimulate cGMP (both P=NS), in contrast to AS (n=5 myocyte preparations). D Furthermore, the pure NO
N
donor DEA/NO, but not AS, releases significant amounts of NO
N in a concentration-dependent manner over 0.1–30 mmol/L (n=3). *P,0.05, **P,0.01
and ***P,0.001 vs control;
#P,0.05 and
###P,0.001 vs Ang II alone;
{P,0.05 and
{{{P,0.001 vs Ang II+AS,
111P,0.001 AS vs same concentration
of DEA-NO.
doi:10.1371/journal.pone.0034892.g007
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first evidence that HNO exerts actions in the myocardium via the
cGMP signaling pathway. As superoxide plays a pivotal role in
triggering the hypertrophic response in the intact heart in vivo,a n di n
cardiomyocytes in vitro [4], HNO/cGMP are an attractive anti-
hypertrophic strategy [3,21]. Our finding that the HNO donor
Angeli’s salt suppresses superoxide production and NADPH oxidase
induction, is further evidenceof HNO superoxide-suppressingactions
in mammalian cells. Given that this action was mimicked by BNP
and 8-BrcGMP, cGMP-generating agents thus appear to mediate
their actions, at least in part, by suppressing cardiomyocyte NADPH
oxidase expression and/or activity. The potential mechanism(s) of
this action (e.g. cGK-mediated phosphorylation of Nox2) warrant
further investigation.
Downstream of ROS, p38MAPK activation is a critical
mediator of pathological cardiomyocyte hypertrophy induced by
neurohumoral activation [2,3,36,37]; cardiomyopathy often re-
sults. In contrast, Akt promotes physiological hypertrophy and
prevents apoptosis [2,38]. A similar role for ERK1/2 in
cardiomyocyte survival and physiological hypertrophy has been
proposed [2,39]. Although Ang II- and ET1-induced cardiomy-
ocyte ERK1/2 activation is often evident in vitro [2,3,30,39],
ERK1/2 does not contribute to pathological hypertrophy in vivo
[40]. Interestingly, Angeli’s salt selectively blunts Ang II-induced
phosphorylation of p38MAPK. As shown in Figure 4, the actions
of Angeli’s salt are dependent on cGMP/cGK-I. MAPK
phosphatase-1 (MKP-1) dephosphorylation of p38MAPK lies
immediately downstream of cGK-I [3,21]. It is thus possible that
Angeli’s salt enhances MKP-1 activity, to mediate the reduced
p38MAPK phosphorylation observed here. Ang II-induced
phosphorylation of both Akt and ERK1/2 however remained
elevated after treatment with the HNO donor, despite normali-
zation of three distinct parameters of cardiomyocyte hypertrophy
(cardiomyocyte size, protein synthesis and hypertrophic gene
expression). Given the cardioprotective properties of Akt [3,38],
the ability of HNO to inhibit cardiomyocyte hypertrophy in the
face of preserved Akt signaling is a desirable trait.
The antihypertrophic effects of HNO are markedly attenuated
by KT5823 or ODQ. Further, cardiomyocyte superoxide
upregulation, a key trigger of cardiomyocyte hypertrophy
[3,21,36], is completely prevented by both KT5823 and ODQ,
leaving no residual cGMP-independent HNO actions. Although it
is possible that the modest, apparently residual, component of the
antihypertrophic actions of Angeli’s salt that are not accounted for
by KT5823 or ODQ could be due to calcitonin gene-related
peptide (CGRP), this is probably unlikely. CGRP has been
identified as a mediator of a component of HNO vasorelaxation
[7]. The effects of CGRP on cardiac hypertrophy remain to be
resolved however, with pro-hypertrophic effects observed in vitro
[41] and antihypertrophic effects in vivo [42]. Further, superoxide
is a key trigger of cardiomyocyte hypertrophy[3,21], yet there was
no parallel residual component of cardiomyocyte superoxide levels
in Ang II-treated myocytes not prevented by KT5823 or ODQ.
Robust sGC-independent cardiovascular actions of HNO linked to
its reactivity with thiols include ryanodine receptors, protein N-
nitrosation and S-glutathiolation, and activation of sarcoplasmic
reticulum Ca
2+-ATPase (SERCA) [10–12,43]. Indeed, acute
supra-pharmacological concentrations of Angeli’s salt (up to 500-
fold of those used here) directly activate SERCA, via S-
glutathiolation at cysteine residue 674 [43] and disulfide bond
formation on phospholamban (preventing its inhibition of
SERCA) [44]. Thus, HNO-selective, thiol-mediated interactions
independent of cGMP likely explain the inotropic and lusitropic
actions of Angeli’s salt [11,43]. Our findings show in contrast that
the antihypertrophic actions of HNO in contrast are critically
dependent on cGMP.
Figure 8. Mechanism of antihypertrophic action of HNO in cardiomyocytes. Angeli’s salt utilizes HNO/sGC/cGMP/cGK-I signaling to
suppress key triggers of the hypertrophic response, including expression and activity of NADPH oxidase (Nox2 subunit, a major source of reactive
oxygen species, ROS) and activity of p38MAPK (the latter possibly as a result of enhanced activity of MAPK phosphatase-1, MKP-1). Activity of the cell
survival kinase Akt (and its downstream target GSK-3b) remain intact in the presence of Angeli’s salt. Cardiomyocyte hypertrophic responses across
cell size, de novo protein synthesis and upregulated expression of b-myosin heavy chain are all ameliorated by HNO in the face of preserved
cardiomyocyte ERK1/2 activation. Both the antihypertrophic and antioxidant actions of HNO are mediated via serial activation of sGC, cGMP
production and cGK-I stimulation. Dashed lines indicate sites of inhibition. See text for references.
doi:10.1371/journal.pone.0034892.g008
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clinical use of traditional nitrovasodilators in the management of
patients suffering hypertrophy/failing cardiac pathologies is
limited, firstly by the phenomenon of ‘‘nitrate tolerance’’ [45].
In addition superoxide, generated in excess amounts in cardiac
hypertrophy and failure, rapidly reacts with NO [3]. HNO donors
offer considerable advantage over traditional NO
N donors as the
redox siblings exhibit quite distinct pharmacology, both in vitro and
in vivo. HNO donors neither exhibit cross-tolerance with organic
nitrates (e.g. glyceryl trinitrate), nor do they induce tolerance to
their own actions [20]. In addition, unlike NO
N, HNO is resistant
to scavenging by ROS [17–19]. Whilst the preference of HNO for
Fe
3+- versus Fe
2+-heme groups [46] was initially thought to
potentially permit HNO activation of the NO
N-insensitive,
oxidized form of sGC; this concept has now been refuted
[35,47]. Importantly, HNO elicits hemodynamic effects favorable
in settings of cardiac remodeling and failure. This includes a
marked positive inotropic effect that is both load- and reflex-
independent, and persists even in failing myocardium in vivo.
Moreover, HNO potentiates b-adrenergic inotropic responses in
the failing heart [8,9,48]. These observations are all in direct
contrast to conventional nitrovasodilators [9,10,17,20].
Limitations of the study
Our detailed investigation of the antihypertrophic actions of
Angeli’s salt and BNP, and the insights obtained into their
mechanisms of action, were performed in a single cardiomyocyte
strain and phenotype. The large majority of in vitro studies
addressing cardiomyocyte hypertrophy similarly use neonatal rat
cardiomyocyte preparations [21,22,28,49,50]. The antihyper-
trophic actions of Angeli’s salt in adult cardiomyocytes may
warrant further investigation. Cardiomyocytes isolated from adult
mouse hearts are obtained in too few numbers, with too limited a
timeframe of viability. We have previously demonstrated however
that the antihypertrophic actions of BNP, like those of other
cGMP-dependent antihypertrophic interventions, are observed in
adult rat cardiomyocytes and/or the intact heart [22–26].
Hypertrophic responses in these settings are studied over a much
shorter time-frame (2 h) and thus preclude assessment of changes
in cell size.
Concluding remarks
We now propose that stimulators of sGC that are not susceptible
to ROS-mediated inactivation, and indeed suppress cardiomyo-
cyte ROS generation, represent a superior approach to exploiting
the antihypertrophic actions of the sGC/cGMP system in the
heart. In conclusion, the present study suggests that HNO prevents
acute cardiac hypertrophic responses (up to 48 h); cGMP-
dependent suppression of cardiomyocyte NADPH oxidase and
p38MAPK (key triggers of the hypertrophic response) likely
contribute to these antihypertrophic actions (illustrated in
Figure 8). Our findings indicate that longer-term studies of the
antihypertrophic effects of this new class of agent in vivo are
warranted. Given these potent antihypertrophic and superoxide-
suppressing actions shown here, together with their established
positive inotropic and vasodilatory actions, HNO donors may
hence form the basis of more effective therapeutics for the clinical
management of cardiac hypertrophy, alone or in combination
with standard care.
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